Gage NM, Juranek J, Filipek PA, Osann K, Flodman P, Isenberg AL et al
3.1.2 Other PEDs This group included other substances prohibited by WADA, such as non-approved substances (BPC-157) from Section S0, other anabolic agents (clenbuterol and SARMs) from Subsection S0, S1.2, peptide hormones and their releasing factors (AOD-9604, hGH 176-191, CJC-1295, ibutamoren, ipamorelin, and growth hormone-releasing peptide) from S2.2, growth factors and growth factor modulators (thymosin-4 and its derivative TB-500) from S2.3, beta-2 agonists (salbutamol and indacaterol) from S3, metabolic modulators (meldonium, GW1516, SR9009, SR9011, and insulins) from Section S4.4, and thyroid hormones
Diabetes 57 , 19261934 (2008)
In between-drug comparisons, tirzepatide 15 mg and 10 mg outperformed semaglutide 1.0 mg and 0.5 mg and tirzepatide 5 mg was superior to semaglutide 0.5 mg, while no differences were found between semaglutide 2.0 mg and any of the tirzepatide doses (ESM Table 9)
Typically, healthcare providers will start patients on a lower dose of Ozempic and gradually increase it over a period of time
KosiborodMNAbildstrmSZBorlaugBAButlerJRasmussenSDaviesMet alSemaglutide in patients with heart failure with preserved ejection fraction and obesity